The Ohio Compliance Compass: Your Roadmap to Healthcare Operations in the Buckeye State

2026-06-04

Ohio presents a unique blend of opportunity and stringent regulatory oversight for healthcare providers. This comprehensive guide unpacks the state's corporate practice of medicine, evolving telehealth laws, nuanced controlled substance rules, and critical compliance pitfalls, offering a definitive roadmap for success.

Ohio, often seen as a bellwether state, offers a robust healthcare market ripe for innovation and expansion. However, the Buckeye State's regulatory landscape is anything but straightforward. From its strict corporate practice of medicine (CPOM) doctrine to its proactive stance on telehealth and controlled substance oversight, Ohio demands meticulous attention to compliance. For telehealth founders, national practice operators, and healthcare investors, understanding these intricacies is not just advisable—it's imperative for sustainable growth and mitigating significant legal and financial risks.

> For more on this topic, see our analysis: [Arizona's Healthcare Frontier: Navigating CPOM, Telehealth, and Prescribing in the Grand Canyon State — Updated for 2026](/blog/arizona-healthcare-frontier-cpom-telehealth-prescribing).

The Ohio Corporate Practice of Medicine Doctrine: Navigating Autonomy and Investment

Ohio stands firm as a strict Corporate Practice of Medicine (CPOM) state, a foundational principle that dictates who can employ physicians and control their professional judgment. Under Ohio Revised Code (ORC) Chapter 4731, only licensed individuals and specific entities, such as hospitals and certain non-profit organizations, may practice medicine. This means a lay corporation generally cannot employ physicians, directly engage in the practice of medicine, or interfere with a physician's independent medical judgment.

Key Implications for Healthcare Businesses: * Management Services Organizations (MSOs): The CPOM doctrine heavily influences the structuring of MSOs in Ohio. While MSOs can provide administrative, non-clinical services (e.g., billing, marketing, IT, real estate) to professional medical corporations, they cannot exercise control over clinical decisions, employ licensed medical professionals, or split fees with the professional entity. The economic relationship between the MSO and the professional corporation must be structured to ensure the MSO does not derive revenue directly from the provision of medical services or influence clinical care. * Fee Splitting Prohibitions: Ohio has robust prohibitions against fee splitting, reinforcing the CPOM doctrine. Licensed providers cannot share fees with unlicensed individuals or entities for patient referrals or professional services. This extends to indirect arrangements that could be construed as incentivizing referrals. * Enforcement Context: The State Medical Board of Ohio (SMBO) actively monitors and enforces CPOM violations. Practices found to be in violation face severe penalties, including professional license suspension or revocation, civil fines, and even criminal charges in egregious cases. Recent years have seen increased scrutiny of models perceived as blurring the lines between administrative support and clinical control, especially with the proliferation of investor-backed healthcare ventures.

For any entity considering operations in Ohio, a foundational understanding of CPOM and a meticulously crafted MSO agreement, reviewed by Ohio-specific legal counsel, is non-negotiable. This protects both the corporate entity and the individual licensed providers.

Ohio's Telehealth Framework: From Pandemic Response to Permanent Fixture

Ohio has embraced telehealth, moving beyond temporary pandemic measures to establish a permanent and comprehensive regulatory framework. House Bill 122 (effective February 2022) was a landmark piece of legislation that codified many pandemic-era flexibilities and introduced new provisions, making Ohio a favorable state for telehealth expansion, provided compliance is met.

Core Telehealth Provisions: * Definition: HB 122 provides a broad definition of telehealth, encompassing various synchronous and asynchronous technologies used to deliver healthcare services remotely. * Payment Parity: The law mandates commercial insurance plans to provide coverage and reimbursement for telehealth services at the same rate as in-person services, a significant boon for telehealth providers. Medicaid also covers a wide array of telehealth services. * Establishing the Patient-Provider Relationship: Ohio generally permits the establishment of a bona fide physician-patient relationship through telehealth, provided the standard of care is met. This often means thorough patient history, appropriate diagnostic methods, and clear documentation. An initial in-person visit is not universally required, a flexibility crucial for remote care. * Informed Consent: Obtaining proper informed consent for telehealth services is critical. Patients must understand the nature of telehealth, its limitations, privacy considerations, and emergency protocols. * Prescribing: While generally permitted, specific rules apply, particularly for controlled substances (discussed below). * Privacy and Security: Telehealth services must adhere to HIPAA and other relevant state and federal privacy regulations, ensuring secure data transmission and storage.

Provider Licensing and Scope of Practice in Ohio

Practicing healthcare in Ohio, regardless of whether it's in-person or via telehealth, necessitates licensure by the appropriate state board.

Physicians (MDs/DOs): The State Medical Board of Ohio (SMBO) governs physician licensure. Telehealth providers must hold an active Ohio license. Ohio is also a member of the Interstate Medical Licensure Compact, facilitating an expedited pathway for eligible physicians licensed in other compact states.
Nurses (RNs, NPs, CRNAs): The Ohio Board of Nursing (OBN) licenses nurses. Advanced Practice Registered Nurses (APRNs), including Nurse Practitioners (NPs), operate under Standard Care Arrangements (SCAs) with collaborating physicians. These SCAs meticulously define the scope of practice, responsibilities, and oversight requirements. For telehealth, the SCA must explicitly address the provision of remote care.
Physician Assistants (PAs): The SMBO also licenses PAs. PAs practice under a Supervision Agreement with a supervising physician, detailing the PA's duties and the physician's oversight. Like NPs, PAs providing telehealth must have their supervision agreement explicitly cover this modality.

It is paramount for practices to ensure that all providers are appropriately licensed and that their scope of practice, including any collaborative or supervisory agreements, explicitly permits the services being rendered, particularly through telehealth.

Controlled Substances in the Buckeye State: A High-Stakes Environment

Ohio maintains some of the nation's most stringent regulations regarding controlled substance prescribing, dispensing, and monitoring. This is an area of intense focus for the SMBO and other state agencies, with severe penalties for non-compliance.

Key Ohio-Specific Rules: * Ohio Automated Rx Reporting System (OARRS): Prescribers are mandated to consult OARRS before prescribing or dispensing an opioid analgesic or benzodiazepine, and periodically thereafter. OARRS is a powerful tool for preventing drug diversion and identifying at-risk patients, and failure to use it appropriately is a common enforcement trigger. * Prescribing Limitations: Ohio has specific limits on initial opioid prescriptions for acute pain (e.g., generally a 7-day supply for adults, 5-day for minors, with exceptions). These rules also apply to telehealth prescriptions. * Telehealth Prescribing for Controlled Substances: Post-Public Health Emergency (PHE), Ohio largely reverted to requiring an initial in-person examination for Schedule II controlled substances, with some narrow exceptions for established patient relationships or certain mental health medications. Prescribing Schedule III-V via telehealth is generally permitted if a legitimate patient-provider relationship has been established and the standard of care is met.

Federal Overlays and Their Impact on Ohio Practices: * DEA Rescheduling of Marijuana (Intelligence Item 2): While Ohio has a medical marijuana program, federal rescheduling of marijuana from Schedule I to Schedule III would have profound implications. It could open doors for broader prescribing, research, and potentially insurance reimbursement. Ohio practices offering cannabis-adjacent services should closely monitor the DEA's restarted rescheduling hearings. However, no operational changes should be made until a final rule is issued. * DEA Quota Overhaul (Intelligence Item 3): The DEA's proposed changes to manufacturing quotas for Schedule I and II controlled substances, while targeting manufacturers, could impact drug availability for Ohio prescribers. Practices experiencing shortages of Schedule II medications (e.g., stimulants, certain opioids) should track this rulemaking and consider submitting comments, as it aims to improve supply chain visibility. * Proposed Schedule I Placement for Diphenidine (Intelligence Item 4) & Butalbital Exemption (Intelligence Item 1): These proposed federal rules are generally low-impact for most Ohio clinical practices but serve as a reminder for any facility dealing with novel chemicals or older formulations to proactively audit their formularies and research protocols to ensure compliance with federal scheduling.

Critical Impact: The FDA's Proposed Exclusion of GLP-1s from 503B Bulks List (Intelligence Item 6)

This federal proposal carries critical implications for Ohio-based weight loss clinics, medspas, and telehealth platforms that utilize compounded semaglutide, tirzepatide, or liraglutide. If finalized, the FDA's proposal to remove these GLP-1 drugs from the 503B bulks list would effectively prohibit outsourcing facilities from compounding them from bulk substances under most circumstances.

Actionable Advice for Ohio Practices: * Immediate Audit: Conduct an immediate audit of your current compounded GLP-1 supply chain. Identify how much of your patient volume relies on 503B-sourced products. * Contingency Planning: Develop robust contingency plans for transitioning patients to FDA-approved branded drugs. This includes understanding the availability and cost implications of branded alternatives. * Submit Comments: The public comment period closes June 29, 2026. If your Ohio practice has clinical evidence of patient need that could inform the agency's final decision, it is imperative to submit formal comments to the FDA docket. Waiting for a final rule is not an option; proactive planning is essential.

Compliance Hot Spots and Enforcement Trends in Ohio

The SMBO, in conjunction with other state agencies, maintains a vigilant watch over healthcare practices. Common areas of enforcement include: * Inappropriate Prescribing: Misuse of OARRS, prescribing outside the standard of care, or violations of opioid prescribing limits are frequent triggers for disciplinary action. * Telehealth Violations: Failure to establish a legitimate patient-provider relationship, inadequate informed consent, or poor documentation in a telehealth setting are closely scrutinized. * CPOM and Fee Splitting: Impermissible corporate structures, MSOs exerting clinical control, or direct/indirect fee-splitting arrangements are high-risk areas. * Advertising and Marketing: False or misleading advertising, especially for cosmetic procedures or weight loss programs, can lead to disciplinary action. This is particularly relevant as more medspas enter the market, offering services related to devices like the newly Class II classified endoscopic suturing devices (Intelligence Item 5). While 510(k) clearance facilitates market entry, marketing claims must accurately reflect FDA classification and avoid equivalency with uncleared alternatives. * Drug Compounding and Device Safety: The Class I Recall of Omnicell syringe labels (Intelligence Item 7) underscores the critical importance of vigilance in drug compounding and device usage. Ohio facilities, including hospital-affiliated outpatient infusion centers or compounding-adjacent medspas, must immediately audit inventory, quarantine affected labels (part numbers 258920028 and 258920029), and confirm labeling accuracy. Failure to respond to such a recall exposes facilities to severe FDA enforcement, state board discipline, and significant liability.

Ohio in Regional Context: A Quick Glance at Neighbors

Comparing Ohio to its neighbors reveals both similarities and crucial distinctions: * Pennsylvania: Similar to Ohio, Pennsylvania is a strict CPOM state, requiring careful MSO structuring. Telehealth parity laws are also in place. * Michigan: Michigan has traditionally been less stringent on CPOM than Ohio but still requires careful consideration of corporate structures. Telehealth regulations have expanded significantly, including robust coverage and reimbursement. * Indiana: Indiana is generally less restrictive on CPOM than Ohio. Its telehealth laws are evolving, with recent legislative efforts to enhance access and reimbursement.

These comparisons highlight the importance of state-specific legal counsel when expanding across jurisdictions, as a compliance model effective in one state may be non-compliant in another.

What This Means For Your Practice: An Ohio Compliance Roadmap

Operating in Ohio's healthcare sector demands a proactive and meticulous approach to compliance. The regulatory environment is dynamic, influenced by both state legislative action and federal agency pronouncements. To thrive, consider the following:

1. Re-evaluate Your Corporate Structure: If operating an MSO model in Ohio, urgently review your agreements and operational practices to ensure strict adherence to the CPOM doctrine and fee-splitting prohibitions. Verify that clinical control remains solely with licensed professionals. 2. Bolster Telehealth Protocols: Ensure your informed consent processes for telehealth are robust, explicit, and well-documented. Verify that all telehealth providers are appropriately licensed by the SMBO or OBN and that their collaborative/supervision agreements address remote care. 3. Audit Controlled Substance Prescribing: Mandate strict adherence to OARRS requirements. Train prescribers on state-specific limitations for initial prescriptions and verify compliance with in-person examination rules for Schedule II substances when necessary. Actively monitor federal DEA proposals for any impact on drug availability or scheduling. 4. Prioritize GLP-1 Contingency Planning: For practices relying on compounded GLP-1s, the FDA's proposed exclusion from the 503B bulks list is a five-alarm fire. Immediately audit your supply chain, develop patient transition plans, and strongly consider submitting comments to the FDA before the June 29, 2026 deadline. This is an immediate and critical business imperative. 5. Stay Current on Device and Drug Safety: Implement robust systems for tracking and responding to FDA recalls, as exemplified by the Omnicell syringe label recall. Your facility's reputation and patient safety depend on swift, decisive action. 6. Invest in Ongoing Training: Regular training for all clinical and administrative staff on Ohio-specific regulations, federal overlays, and new guidance is essential to maintain compliance and mitigate risk.

Ohio offers significant growth potential, but only for those who navigate its complex regulatory landscape with precision and foresight. By embracing a culture of continuous compliance and proactive adaptation, healthcare operators can unlock the Buckeye State's opportunities while safeguarding their practices and patients.